PROTEIN A RESIN MARKET ANALYSIS

Protein A Resin Market, By Product (Natural Protein A and Recombinant Protein A), By Matrix Type (Agarose-based, Glass or Silica Based, and Organic Polymer Based), By Application (Immunoprecipitation and Antibody Purification), By End User (Biopharmaceutical Companies, Clinical Research Laboratories, and Academic Institutes), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

In February 2024, Purolite, an Ecolab company, and Repligen Corporation, a life science company announced the commercial launch of Praesto CH1, a novel 70 μm (micron) agarose-based affinity resin. This resin is specifically designed to purify specialized monoclonal antibodies, including bispecifics and recombinant antibody fragments.
In January 2024, Dutch Oxitope, Developer of antibody and gene therapy products and Norwegian Arxx completed a merger to establish Calluna Pharma Inc. The newly formed company focuses on developing monoclonal antibody therapies aimed at treating inflammatory and fibrotic diseases. Calluna Pharma Inc. successfully raised USD 80.4 million (EUR 75 million) in Series A financing to advance its lead clinical program, CAL101. CAL101 is a monoclonal antibody targeting S100A4, currently in Phase 1 trials for indications related to fibrosis and inflammation.
In March 2020, Avantor, Inc., a prominent global supplier of essential products and services to industries including life sciences, advanced technologies, and applied materials, has introduced a novel recombinant Protein An affinity chromatography resin. This resin is designed specifically for purifying antibodies in the production of monoclonal antibodies (mAbs).